Real-World Effectiveness of Four Types of COVID-19 Vaccines

Vaccines, Год журнала: 2023, Номер 11(5), С. 985 - 985

Опубликована: Май 15, 2023

There is a scarcity of evidence regarding the real-world effectiveness coronavirus disease 2019 (COVID-19) vaccines. This was first study to evaluate four types vaccines against asymptomatic and symptomatic infection, COVID-19 outcomes among general population.This matched comparison group quasi-experimental conducted in Jordan between 1 January 29 August 2021. In part study, 1200 fully vaccinated individuals were with unvaccinated control participants. order measure vaccine effectiveness, infection rates both groups calculated. The second included measuring specific anti-SARS CoV-2 immune cells antibodies.BNT162b2 (Pfizer, New York, NY, USA) showed significantly higher (91.7%) hospitalization (99.5%) than BBIBP-CorV (Sinopharm, Beijing, China) (88.4% 98.7%, respectively) ChAdOx1 nCoV-19 (AstraZeneca, Cambridge, UK) (84.3%, 98.9%, respectively). Sputnik V (Gamaleya Research Institute, Moscow, Russia) asymptomatic, symptomatic, 100%, 66.7%, respectively. highest median anti-spike (S) IgG values seen who received BNT162b2 (2.9 AU/mL) (2.8 levels anti-S decreased after 7 months vaccination BBIBP-CorV. significant decreases number neutralizing antibodies one month seven receiving (from 88.5 75.2 4 Bioequivalent Allergen Unit per milliliter/mL), 69.5 51.5 BAU/mL), 69.2 58.BAU/mL) percentage T found (88.5%).All evaluated this hospitalization, death. Furthermore, BNT162b2, BBIBP-CorV, induced high immunology markers within vaccination.

Язык: Английский

---

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study

Human Vaccines & Immunotherapeutics, Год журнала: 2023, Номер 19(1)

Опубликована: Янв. 2, 2023

Real-world evidence on the effectiveness of COVID-19 vaccines marketed in China against Omicron BA.2.2 variant remains scarce. A case–control study was conducted to estimate vaccine (VE) (inactivated vaccines, an Ad5-nCoV vaccine, and a recombinant protein vaccine). There were 414 cases infected with SARS-CoV-2 828 close contacts whose test results consecutively negative as controls during outbreak Lu'an City, Anhui Province, China, April 2022. The overall adjusted VE infection vaccinated group any 35.0% (95% CI: −9.1–61.3%), whereas for booster vaccination 51.6% 15.2–72.4%). Subgroup analysis showed that (65.8%, 95% 12.8–86.6%) while dose inactivated offered no protection. three-dose 48.0% 8.0–70.6%), two-dose 62.9% 1.8–86%). is protection from vaccine. 46.8% 9.5–68.7%) within six months. statistically significant differences between VEs heterologous (VE = 76.4%, 14.3–93.5%) homologous 51.8%, 9.6–74.3%) (P .036). Booster more than full vaccination. campaign after three doses must be urgently conducted.

Язык: Английский

---

Associated organs and system with COVID-19 death with information of organ support: a multicenter observational study

BMC Infectious Diseases, Год журнала: 2023, Номер 23(1)

Опубликована: Ноя. 20, 2023

The organ dysfunction that is associated with death in COVID-19 patients has not been determined multicenter epidemiologic studies. In this study, we evaluated the major association death, concomitant dysfunction, and proportion of multiple failure deaths COVID-19, along information on support.

Язык: Английский

---

Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study

International Journal of Infectious Diseases, Год журнала: 2022, Номер 125, С. 58 - 60

Опубликована: Окт. 8, 2022

We aimed to evaluate COVID-19 messenger RNA vaccine effectiveness during the Delta- and Omicron-predominant periods in Japan.We conducted a population-based cohort study among individuals aged 16-64 years two periods: Delta-predominant period (July 1-December 31, 2021) (January 1-March 29, 2022).When comparing who were vaccinated with those unvaccinated, of second dose against symptomatic infection was 89.8% (95% confidence interval [CI]: 80.5-94.7%) 21.2% CI: 11.0-30.3%) period. The third 71.8% 60.1-80.1%) period.Vaccine decreased but maintained by dose.

Язык: Английский

---

Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination

Human Vaccines & Immunotherapeutics, Год журнала: 2023, Номер 19(2)

Опубликована: Июнь 25, 2023

Although mRNA coronavirus disease 2019 (COVID-19) vaccines have been reported for high effectiveness against symptoms, it remains unclear whether post-vaccination infections are less symptomatic than in vaccine-naive individuals. We included patients with COVID-19 diagnosed by polymerase chain reaction tests during Japan's alpha and delta variant epidemics. symptoms at approximately 4 weeks were compared based on vaccination status. In total, 398 cases (372 26 asymptomatic; 286 unvaccinated, 66 vaccinated one dose, 46 two doses) analyzed. The most common fever (78.4%), fatigue cough (74.4%), loss of taste or smell (62.8%), headache (59.8%). Post-vaccination significantly likely to be symptomatic. Possible confounder-adjusted odds ratios vaccine doses fatigue, dry eyes mouth, insomnia, fever, shortness breath, unusual muscle pains, 0.18 (95% confidence interval [CI]: 0.09–0.38), 0.22 CI: 0.08–0.59), 0.33 0.14–0.80), 0.31 0.15–0.63), 0.36 0.16–0.76), 0.40 0.19–0.82), 0.44 0.22–0.87), respectively. after show milder fewer unvaccinated patients, highlighting the vaccination.

Язык: Английский

---

Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study

Open Forum Infectious Diseases, Год журнала: 2022, Номер 9(12)

Опубликована: Ноя. 24, 2022

Abstract Background Vaccine effectiveness against the severe acute respiratory syndrome coronavirus 2 Omicron BA.2 sublineage in Japan is unknown. We assessed of a third dose COVID-19 mRNA vaccine compared with that doses. Methods performed population-based cohort study using municipality database located Chubu region during BA.1- and BA.2-predominant periods (January 1–March 31, 2022 April 1–27, 2022, respectively). included residents aged ≥16 years who received second at ≥14 days before start each period, regardless dose. data 14 after 2-week intervals from to 10 weeks Cox regression model. was defined as (1 – hazard ratio) × 100 (%). Results In total, 295 705 288 184 individuals were periods, respectively. The infection 62.4% 48.1% 2–3 ≥10 decreased 63.6% (95% confidence interval [CI], 56.4–69.5%) 52.9% CI, 41.1–62.3%) 54.5% 3.0–78.7%) 40.1% 15.1–57.7%) Conclusions A moderately effective BA.1 sublineages, but its by approximately 10% age points vaccination.

Язык: Английский

---

Association of COVID-19 vaccine intake with diagnosis, hospitalization, and oxygenation/ventilation: A longitudinal analysis, 2021-2022, Japan

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Фев. 22, 2024

Limited national-level data exist on COVID-19 vaccine effectiveness against infection outcomes based individual characteristics. We analyzed 19,482 individuals aged 16-81 who responded to baseline (2021) and follow-up (2022) Internet-based surveys. intake (0/1/2+ doses) during the period was examined, included diagnosis, hospitalization, oxygenation/ventilation. Adjusted prevalence ratios (APRs) were computed using Poisson regression models, controlling for characteristics including precautionary measures practiced. 81.6% of respondents received ≥1 dose period. Among those without history at (N=19,182), 10.9% 6.6% reported diagnosis within past year 2 months follow-up, respectively. Respondents 1 or 2+ doses less likely be diagnosed in (APR=0.76 0.43) (APR=0.87 [not statistically significant] 0.51) compared did not. 1,999 with showed lower likelihoods hospitalization (APR=0.78 0.86) receipt oxygenation/ventilation 0.61), although not significant. Considering interaction socioeconomic behavioral characteristics, results supported protective effect infection.

Язык: Английский

---

Association of COVID-19 Vaccine Intake with Diagnosis, Hospitalization, and Oxygenation/Ventilation: A Longitudinal Analysis, 2021–2022, Japan

Vaccines, Год журнала: 2024, Номер 12(11), С. 1264 - 1264

Опубликована: Ноя. 8, 2024

Japan's COVID-19 vaccination campaign achieved high coverage by 2022, yet limited national-level data has hindered evaluations of vaccine effectiveness. This study analyzed the impact vaccines on infection outcomes while considering socioeconomic and behavioral factors in Japanese population.

Язык: Английский

---

Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study

Journal of Epidemiology, Год журнала: 2023, Номер 34(6), С. 278 - 285

Опубликована: Сен. 22, 2023

Background: We evaluated the effectiveness of BNT162b2 vaccine against infection, symptomatic and hospitalization in older people during Delta-predominant period (July 1 to September 30, 2021).

Язык: Английский

---

Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic

Human Vaccines & Immunotherapeutics, Год журнала: 2022, Номер 18(7)

Опубликована: Дек. 2, 2022

Although nationwide immunization with SARS-CoV-2 mRNA vaccines began in February 2021, the evaluation of vaccine effectiveness (VE) using a test-negative design has not been conducted adequately Japan. To evaluate vaccines, we case-control study during periods dominated by Delta and Omicron variants. In total, 518 358 adult participants COVID-19-like symptoms were tested for virus from August to October 2021 (Delta variant predominance) 2022 (Omicron surge), at Kawasaki Saiwai Clinic. During predominance, full vaccination was 90.4% (95% confidence interval [CI]: 82.1-94.8) 97.3% CI: 71.7-99.7) against all COVID-19 moderate-to-severe disease, respectively. However, partial failed show COVID-19. The infection declined 16.1% -81.0 61.1) 2022. Our results indicated that, although showed significant preventive effects these waned surge. best our knowledge, this is first that evaluated VE Japanese population both periods.

Язык: Английский

---